Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody Scheinfeld NDermatol Online J 2005[Mar]; 11 (1): 2Omalizumab (Xolair) is a recombinant humanized monoclonal antibody that blocks the high-affinity Fc receptor of immunoglobulin E (IgE). It is used to treat patients with moderate-persistent to severe-persistent asthma; patients must be older than 12 years, have a positive skin test to a perennial aeroallergen (e.g., dust mites, cats, dogs, and mold), and be symptomatic with inhaled corticosteroids. Omalizumab has a low incidence of side effects, and it is very expensive. The exact dosage of omalizumab dosage is determined by body weight and pretreatment serum total IgE levels. Omalizumab may have a role in the treatment of atopic dermatitis when IgE plays a causal role.|Antibodies, Anti-Idiotypic[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/immunology/pharmacology/*therapeutic use[MESH]|Clinical Trials as Topic[MESH]|Dermatitis, Atopic/*drug therapy[MESH]|Dermatologic Agents/immunology/pharmacology/*therapeutic use[MESH]|Humans[MESH]|Immunoglobulin E/*drug effects[MESH]|Interleukins/immunology[MESH]|Omalizumab[MESH] |